KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2025)

Recursion Pharmaceuticals' Long-Term Deferred Tax history spans 2 years, with the latest figure at $957000.0 for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 50.52% year-over-year to $957000.0; the TTM value through Dec 2025 reached $957000.0, down 50.52%, while the annual FY2025 figure was $957000.0, 50.52% down from the prior year.
  • Long-Term Deferred Tax reached $957000.0 in Q4 2025 per RXRX's latest filing, roughly flat from $957000.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $2.0 million in Q1 2025 to a low of $957000.0 in Q2 2025.